Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureSunil V. Badve, An S. De Vriese, Martin Gallagher
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Low-dose rivaroxaban and cardiovascular events in advanced kidney disease: the TRACK randomized clinical trial.
10.1001/jama.2026.9379 · 2026
Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients.
10.1681/asn.2008080824 · 2009
Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis.
10.7326/m19-0087 · 2019
Oral anticoagulant initiation in patients with kidney failure on hemodialysis newly diagnosed with atrial fibrillation (2007-2020): an observational study of trends and disparities.
10.1016/j.xkme.2024.100926 · 2024
Apixaban with antiplatelet therapy after acute coronary syndrome.
10.1056/nejmoa1105819 · 2011
Dose-finding study of rivaroxaban in hemodialysis patients.
10.1053/j.ajkd.2015.01.022 · 2015
No additional external references are available.